ArticleBMC microbiology2026
Phenotypic and genotypic characterization of carbapenem resistant Klebsiella pneumoniae clinical isolates from Damietta, Egypt.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe notable emergence of carbapenemase production is a critical problem threatening human health worldwide. Hence, this study aimed to monitor the prevalence of carbapenemase-producing Klebsiella pneumoniae in Damietta, Egypt. Additionally, the study investigated the association of carbapenemase producers and certain virulence traits, including biofilm formation and colibactin genotoxin.
methodsThis study included 86 clinical isolates of Klebsiella pneumoniae collected from various clinical analytical laboratories and private clinics in Damietta, Egypt, between June 2023 and May 2024. Carbapenemase production was determined by various phenotypic assays (CarbaNP/mCIM/eCIM). Genotypic detection of carbapenemase-encoding genes (blaNDM, blaKPC, blaVIM, blaIMP, and blaOXA-48) and certain virulence genes (clbA, clbB, mrkD, and fimH) was performed using multiplex PCR. Chi-square and Fisher’s exact tests were used for statistical analysis.
resultsIn the current study, 44.2% (38/86) of Klebsiella pneumoniae were identified as carbapenemase producers. All carbapenemase-producing Klebsiella pneumoniae (38/38, 100%) were positive by mCIM, while 92.1% (35/38) were positive by CarbaNP, and 65.8% (25/38) were positive by eCIM. The blaNDM, blaOXA-48, and blaKPC genes were detected in 71%, 36.8%, and 5.2% of the tested isolates, respectively. No blaIMP or blaVIM were detected. Different biofilm formation capabilities were observed among carbapenemase producers: moderate (42.1%), strong (36.8%), weak (13.1%), and non-biofilm (7.8%). The capacity for biofilm formation differed significantly between carbapenemase-producing and non-producing Klebsiella pneumoniae. The mrkD gene was significantly associated with carbapenemase-producing Klebsiella pneumoniae in contrast to fimH and colibactin-encoding genes.
conclusionsThis study provides valuable insights into the continuous emergence of carbapenemase-producing Klebsiella pneumoniae, which poses a serious clinical and public health concern. A significant association was observed between carbapenemase producers and certain virulence factors. This emphasizes the urgent need for ongoing monitoring, effective stewardship programs, intensive surveillance, and strict infection control policies to control the spread of such highly resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.